Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

Resource type
Journal Article
Authors/contributors
Title
Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Abstract
The Infectious Diseases Society of America and the American Association for the Study of Liver Diseases have collaboratively developed evidence-based guidance regarding the diagnosis, management, and treatment of hepatitis C virus (HCV) infection since 2013. A panel of clinicians and investigators with extensive infectious diseases or hepatology expertise specific to HCV infection periodically review evidence from the field and update existing recommendations or introduce new recommendations as evidence warrants. This update focuses on changes to the guidance since the previous 2020 published update, including ongoing emphasis on recommended universal screening; management recommendations for incomplete treatment adherence; expanded eligibility for simplified chronic HCV infection treatment in adults with minimal monitoring; updated treatment and retreatment recommendations for children as young as 3 years old; management and treatment recommendations in the transplantation setting; and screening, treatment, and management recommendations for unique and key populations.
Publication
Clinical Infectious Diseases
Date
2023-05-25
Pages
ciad319
Journal Abbr
Clinical Infectious Diseases
Accessed
5/28/23, 11:18 AM
ISSN
1058-4838
Short Title
Hepatitis C Guidance 2023 Update
Library Catalog
Silverchair
Citation
Bhattacharya, D., Aronsohn, A., Price, J., Lo Re, V., III, & the AASLD-IDSA HCV Guidance Panel. (2023). Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases, ciad319. https://doi.org/10.1093/cid/ciad319
SOLID ORGANS AND MCSS
Link to this record